Guptill, J. T., S. M. Raja, V. C. Juel, E. B. Walter, M. Cohen-Wolkowiez, H. Hill, E. Sendra, B. Hauser, P. Jackson, and G. K. Swamy. “Safety, Tolerability and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B.” Antimicrob Agents Chemother, April 19, 2021. https://doi.org/10.1128/AAC.02329-20.
Geeta Krishna Swamy, MD
Dr. Geeta Swamy, MD, became Vice Chair for Research and Faculty Development in the Department of Obstetrics and Gynecology on March 1, 2018. In this dual role, Dr. Swamy oversees strategic development and administration of the Department’s basic, translational and clinical research programs, as well as implements and oversees programs to support development and mentorship for all faculty at all levels.
Dr. Swamy has also been instrumental in developing and leading the School of Medicine’s Research Regulatory and Compliance initiatives, first as Chair of the IRB and then as Senior Associate Dean for Clinical Research for Regulatory Oversight and Research Initiatives. In 2018, she became Vice Dean for Scientific Integrity and Associate Vice President for Research for Duke University. In these roles she oversees the Duke Office of Scientific Integrity (DOSI) which houses the Advancing Scientific Integrity, Services, & Training (ASIST) initiative, conflict of interest, clinical quality management, incident response in research, and research misconduct. She also oversees the Duke Office of Research Initiatives which includes the research onboarding and navigation programs.
Dr. Swamy has dedicated her career to advancing research in women’s health and to mentoring faculty and trainees. She is an internationally recognized clinician-researcher, and an expert and nationally-recognized leader in the field of maternal immunization and vaccination in pregnancy. Her research has been funded by the National Institutes of Health (NIH), Centers for Disease Control (CDC), Environmental Protection Agency (EPA) and others. She currently serves as the Co-Principal Investigator for the NIH-NIAID Vaccine Treatment and Evaluation (VTEU) and CDC-funded Clinical Immunization Safety Assessment, and has published over 100 peer-reviewed manuscripts. Dr. Swamy has been the Director of the Duke Perinatal Research Center since 2010. Dr. Swamy's focused area of interests are perinatal infection, maternal immunization and preterm birth.
Education and Training
- Resident, Obstetrics And Gynecology, University of Pittsburgh, 1997 - 2001
- M.D., University of North Carolina - Chapel Hill, 1997
Selected Grants and Awards
- Population Health Research Support IDIQ Base
- Duke Women's Reproductive Health Research Scholars
- 2020 CISA 04-COVID Maternal Study
- Vaccine and Treatment Evaluation Units (VTEU)
- Duke CTSA (TL1)
- Eunice Kennedy Shriver NICHD Cooperative Multicenter Neonatal Research Network
- CISA 2018-2019- Clinical Consult - Opt 1
- RTOP 2018 CISA 01 Flublok Lead Task 2
- RTOP 2018 CISA 01 Flublok Lead Task 3
- RTOP 2018 CISA 01 Flublok Lead Task 4
- Pulmonary Complications in a Birth Cohort after a Randomized Trial of Exposure to Antenatal Corticosteroids: the ALPS Follow-Up Study
- Population Health Research Support - Study of Pregnancy and Neonatal Health (SPAN) Task A
- Affecting Culture Change: Building Unit-Level Infrastructure to Mitigate Research Integrity Risk
- CISA 2020-2021- Clinical Consult - Opt 1
- CIVICS Component C - Option 1
- RTOP 2018 CISA 01 Flublok Lead Base
- RTOP 2018 CISA 01 Flublok Lead Task 1
- Adaptive COVID-19 Treatment Trial (ACTT)
- Pulmonary Complications in a Brith Cohort after a Randomized Trial of Exposure to Antenatal Corticosteroids: the ALPS Follow-Up Study Capitation
- VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Option 1
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- VTEU Task Area C Option 2-3 Protocol 15-0020.B1C1.0040
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- VTEU Protocol Implementation Option 1
- The relationship between maternal ZIKV-specific and ADE antibodies and fetal outcome
- MFMU Network Study - ALPS FSN
- NICHD Maternal Fetal Medicine Units Network
- VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base
- VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base-A
- Rapid, Near Patient Nucleic Acid Testing for Infant Cytomegalovirus (CMV) Infection
- RSV- M-301
- VTEU Task Area C Option 2-2 Protocol 15-0020.B1C1.0040
- VTEU RTOP FY.2019.A1B1C1D1.0103 - Task A - Base
- MFMU Network Studies
- CISA: 2015 CISA 03 - Lead Site Base Task: Maternal Tdap and IIV Study (Lead)
- Duke Research Training Program for Pediatricians
- Duke CTSA (UL1)
- RSV-M-203: Study M-203 - A Phase II Randomized, Observer-blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) Fusion (F)
- CISA Task Order No. 3 Tdap Safety in Pregnant Women
- A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women
- SAFETY AND IMMUNOGENICITY OF TDAP VACCINE IN HEALTHY PREGNANT WOMEN, SAFETY IN THEIR NEONATES, AND EFFECT OF MATERNAL IMMUNIZATION ON INFANT IMMUNE RESPONSES TO DTAP VACCINE - DMID 05-0048
- DMID 09-0005 Safety and Immunogenicity
- Effectiveness of a Vaccination Program in the Community ObGyn Setting
- 09-0056 A Phase II Study in Pregnant Women to Assess the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Inactivated Influenza Vaccine Administered at Two Dose Levels
- A randomized double-blind trial on the safety and immunogenicity of inactivated trivalent influenza vaccine in pregnant women.
- Prevention of Influenza in Infants by Immunization of Their Contacts in the Household (PIIITCH study)
Dotters-Katz, Sarah K., Hailey Harris, Sarahn M. Wheeler, Geeta K. Swamy, and Brenna L. Hughes. “Specialized prenatal care delivery for coronavirus disease 2019-exposed or -infected pregnant women.” Am J Obstet Gynecol 224, no. 3 (March 2021): 325–27. https://doi.org/10.1016/j.ajog.2020.11.025.
Craig, Amanda M., Brenna L. Hughes, and Geeta K. Swamy. “Coronavirus disease 2019 vaccine in pregnant women: not so far! The importance of counseling and the need for evidence-based data.” Am J Obstet Gynecol Mfm 3, no. 3 (February 1, 2021): 100323. https://doi.org/10.1016/j.ajogmf.2021.100323.
Tita, Alan T. N., Lindsay Doherty, William A. Grobman, Uma M. Reddy, Robert M. Silver, Gail Mallett, Madeline Murguia Rice, et al. “Maternal and Perinatal Outcomes of Expectant Management of Full-Term, Low-Risk, Nulliparous Patients.” Obstet Gynecol 137, no. 2 (February 1, 2021): 250–57. https://doi.org/10.1097/AOG.0000000000004230.
Harris, H. M., S. K. Dotters-Katz, S. Wheeler, G. K. Swamy, and B. Hughes. “Cohorting prenatal care during the COVID-19 pandemic.” In American Journal of Obstetrics and Gynecology, 223:985–985, 2020.
Darling, A. J., J. Federspiel, L. Wein, G. K. Swamy, and S. K. Dotters-Katz. “Late-season influenza: Don't let your guard down!.” In American Journal of Obstetrics and Gynecology, 223:968–69, 2020.
Swamy, Geeta K., Torri D. Metz, Kathryn M. Edwards, David E. Soper, Richard H. Beigi, James D. Campbell, Luca Grassano, et al. “Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.” Vaccine 38, no. 44 (October 14, 2020): 6930–40. https://doi.org/10.1016/j.vaccine.2020.08.056.
Silver, Robert M., Madeline Murguia Rice, William A. Grobman, Uma M. Reddy, Alan T. N. Tita, Gail Mallett, Kim Hill, et al. “Customized Probability of Vaginal Delivery With Induction of Labor and Expectant Management in Nulliparous Women at 39 Weeks of Gestation.” Obstet Gynecol 136, no. 4 (October 2020): 698–705. https://doi.org/10.1097/AOG.0000000000004046.